SCHEMBL1869725

SCHEMBL1869725

CCCC(=O)OC[C@H](O)[C@H]1OC(=O)C(OC(=O)CCC)=C1O

nearest known ligand 0.66

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 3/20 0.66
HSPD1 P10809 1/20 0.66
HSPE1 P61604 1/20 0.66
TST Q16762 1/20 0.66
RECQL P46063 1/20 0.66
BLM P54132 1/20 0.66
TDP1 Q9NUW8 1/20 0.66
TYR P14679 1/20 0.42
LMNA P02545 3/20 0.40
L3MBTL1 Q9Y468 1/20 0.40
PPM1A P35813 2/20 0.39
NLRP3 Q96P20 2/20 0.38
KMT2A Q03164 2/20 0.35
KDM4E B2RXH2 1/20 0.35
DUSP3 P51452 1/20 0.35
MEN1 O00255 1/20 0.35
LPAR6 P43657 1/20 0.34
LPAR1 Q92633 1/20 0.34
LPAR4 Q99677 1/20 0.34
LPAR5 Q9H1C0 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31676474 1.00 MAPT (0.66) MAPTHSPD1HSPE1TSTRECQL
SCHEMBL1974137 0.91 MAPT (0.80) MAPTHSPD1HSPE1TSTRECQL
SCHEMBL29804572 0.91 MAPT (0.80) MAPTHSPD1HSPE1TSTRECQL
SCHEMBL22099880 0.91 MAPT (0.80) MAPTHSPD1HSPE1TSTRECQL
SCHEMBL7805056 0.91 MAPT (0.80) MAPTHSPD1HSPE1TSTRECQL
SCHEMBL6429749 0.91 MAPT (0.80) MAPTHSPD1HSPE1TSTRECQL
SCHEMBL4394069 0.86 MAPT (0.81) MAPTHSPD1HSPE1TSTRECQL
SCHEMBL4574133 0.86 MAPT (0.81) MAPTHSPD1HSPE1TSTRECQL
SCHEMBL4394073 0.86 MAPT (0.81) MAPTHSPD1HSPE1TSTRECQL
SCHEMBL15153093 0.86 MAPT (0.62) MAPTHSPD1HSPE1TSTRECQL

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20150273066-A1 CONVENIENTLY IMPLANTABLE SUSTAINED RELEASE DRUG COMPOSITIONS RAMSCOR INC (US) 2015-10-01 US claimed
US-20080038316-A1 Conveniently implantable sustained release drug compositions RAMSCOR, INC. 2008-02-14 US claimed
US-6881278-B2 Flux for solder paste SHOWA DENKO K.K. (JP) 2005-04-19 US claimed
US-20030200836-A1 Flux for solder paste SHOWA DENKO K.K. 2003-10-30 US claimed
US-20020046627-A1 Solder powder, flux, solder paste, soldering method, soldered circuit board, and soldered joint product SHOWA DENKO K.K. (JP) 2002-04-25 US claimed
US-20250367165-A1 EMERGENCY EYE WASH LEBRUN LABS LLC (US) 2025-12-04 US disclosed
US-20250289840-A1 RNA STABILIZING SUBSTANCES AND METHODS OF USE TEAM MEDICAL, LLC 2025-09-18 US disclosed
US-20250262123-A1 EMERGENCY EYE WASH LEBRUN LABS LLC 2025-08-21 US disclosed
US-20240115595-A1 MATERIAL COMPOSITIONS AND METHODS OF USE IMPROVING RNA STABILITY TEAM MEDICAL, LLC (US) 2024-04-11 US disclosed
WO-2024055011-A1 MATERIAL COMPOSITIONS AND METHODS OF USE IMPROVING RNA STABILITY TEAM MEDICAL, LLC (US) 2024-03-14 WO disclosed
US-10744202-B2 Sustained release eye drop formulations RAMSCOR, INC. (US) 2020-08-18 US disclosed
US-20180289810-A1 SUSTAINED RELEASE EYE DROP FORMULATIONS RAMSCOR, INC. (US) 2018-10-11 US disclosed
US-8541413-B2 Sustained release eye drop formulations RAMSCOR, INC. (US) 2013-09-24 US disclosed
US-20110111006-A1 CONVENIENTLY IMPLANTABLE SUSTAINED RELEASE DRUG COMPOSITIONS RAMSCOR, INC. (US) 2011-05-12 US disclosed
US-20090136445-A1 SUSTAINED RELEASE EYE DROP FORMULATIONS RAMSCOR, INC. 2009-05-28 US disclosed
US-20080038316-A1 Conveniently implantable sustained release drug compositions RAMSCOR, INC. 2008-02-14 US disclosed
US-6881278-B2 Flux for solder paste SHOWA DENKO K.K. (JP) 2005-04-19 US disclosed
US-20030200836-A1 Flux for solder paste SHOWA DENKO K.K. 2003-10-30 US disclosed
US-20020046627-A1 Solder powder, flux, solder paste, soldering method, soldered circuit board, and soldered joint product SHOWA DENKO K.K. (JP) 2002-04-25 US disclosed
US-20010042779-A1 Solder paste SHOWA DENKO KABUSHIKI KAISHA (JP) 2001-11-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240115595-A1 MATERIAL COMPOSITIONS AND METHODS OF USE IMPROVING RNA STABILITY RBM22, HNRNPUL2, HNRNPUL1 MAPT 773/4885HSPD1 1126/4885HSPE1 1092/4885
US-20250289840-A1 RNA STABILIZING SUBSTANCES AND METHODS OF USE SYNCRIP, SNRPA, RNASE1 MAPT 953/4885HSPD1 1596/4885HSPE1 2003/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.